Article

September 25, 2012

ACOs Have Potential for Big Savings, Reduced Readmission

New payment models used in accountable care organizations (ACOs) have shown considerable promise, yielding overall savings and reduced readmission rates, according to a recent study conducted by the Dartmouth Institute for Health Policy and Clinical Practice.

The study, published in the Sept. 12 issue of The Journal of the American Medical Association, examined the cost savings associated with the Physician Group Practice Demonstration (PGPD), a Medicare program that ran from 2005 to 2010 and closely resembled current ACOs.

Read the full story: http://bit.ly/OxM3kI

Source: Healthcare Finance News

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Nicolas Ferreyros, managing director, Community Oncology Alliance

Merrill H. Stewart, MD

David Awad, PharmD, BCOP

Merrill H. Stewart, MD

David Awad, PharmD, BCOP

Coral Omene, MD, PhD, sitting for a vieo interview

Coral Omene, MD, PhD, sitting for a vieo interview

David Awad, PharmD, BCOP

Screenshot of Coral Omene, MD, PhD

Related Content

FDA approved | Image credit: DG-Studio – stock.adobe.com

Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Managed Care Cast

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

The mean percent change in body weight from the obesity cohort from baseline to 52 weeks ranged from −12.3% to −16.2% to −16.2%. | Image Credit: ricka_kinamoto - stock.adobe.com

July 1st 2025

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

Sabrina McCrear

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com

June 30th 2025

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

CLL cells | Image Credit: © sovova - stock.adobe.com

June 30th 2025

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

Jared Kaltwasser

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

Related Content

FDA approved | Image credit: DG-Studio – stock.adobe.com

Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Managed Care Cast

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

The mean percent change in body weight from the obesity cohort from baseline to 52 weeks ranged from −12.3% to −16.2% to −16.2%. | Image Credit: ricka_kinamoto - stock.adobe.com

July 1st 2025

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

Sabrina McCrear

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com

June 30th 2025

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

CLL cells | Image Credit: © sovova - stock.adobe.com

June 30th 2025

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

Jared Kaltwasser

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions